Key result
Continuous lipoprotein density profiling reliably reveals worse dyslipidemia in untreated versus treated dogs with EPI.
Observational (n=57)
CLPDP is a repeatable and reproducible technique for evaluating dyslipidemia in dogs, demonstrating that enzyme supplementation normalizes lipoprotein profiles in dogs with exocrine pancreatic insufficiency.
CLPDP enables reliable dyslipidemia assessment in canine EPI models; leaves open clinical translation and outcome studies.
Changes in proportions of lipoprotein classes have been described in disease states in humans. In veterinary medicine, hyperlipidemia can cause complications, such as cutaneous xanthomas, liver disease, cholelithiasis, pancreatitis, glomerular disease, lipemia retinalis, or peripheral neuropathy, but there are few reports regarding lipoproteins in diseased animals. For canine serum, we partially validated continuous lipoprotein density profiling (CLPDP), a novel density gradient ultracentrifugation technique. We examined canine lipoproteins separated by CLPDP by transmission electron microscopy (TEM). We compared lipoprotein profiles between healthy control dogs ( n = 29) and dogs with exocrine pancreatic insufficiency (EPI; n = 28) using CLPDP. Dogs with EPI included those untreated (EPI-NT; n = 6) and those treated with enzyme supplementation (EPI-T; n = 22). Our preliminary assay validation showed that CLPDP was repeatable (CV = 11.2%) and reproducible (CV = 10.6%) in canine serum. The diameters of lipoproteins analyzed by TEM were similar to those reported previously. Dogs in the EPI-NT group had more severe dyslipidemia than dogs in the EPI-T group. Dogs in the EPI-T group had lipoprotein profiles similar to healthy control dogs. CLPDP might be a useful tool for evaluating dyslipidemia in dogs.
No takes yet. Share an insight, caveat, or question.
Minamoto et al. (2018) conducted an observational in Exocrine pancreatic insufficiency (n=57). Exocrine pancreatic insufficiency (untreated vs treated) vs. Healthy control dogs was evaluated on Lipoprotein profiles measured by continuous lipoprotein density profiling (CLPDP). Continuous lipoprotein density profiling was repeatable (CV = 11.2%) and reproducible (CV = 10.6%), revealing more severe dyslipidemia in untreated versus treated dogs with EPI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: